Skip to main content
Sinocelltech Group Limited logo

Sinocelltech Group Limited — Investor Relations & Filings

Ticker · 688520 ISIN · CNE100003ZL3 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 659 across all filing types
Latest filing 2023-12-15 AGM Information
Country CN China
Listing Shanghai Stock Exchange 688520

About Sinocelltech Group Limited

https://www.sinocelltech.com/

Sinocelltech Group Limited focuses on the research, development, and commercialization of innovative biologics, including monoclonal antibodies, recombinant proteins, and vaccine candidates. The company's product pipeline addresses therapeutic areas such as oncology, autoimmune disorders, hematology, and infectious diseases. Key offerings include recombinant human coagulation factor VIII for hemophilia A and a range of biosimilars. Sinocelltech leverages an integrated technology platform encompassing early-stage discovery through to large-scale industrial production. This infrastructure supports the development of high-quality biological medicines aimed at addressing unmet medical needs through advanced protein engineering and cell line development.

Recent filings

Filing Released Lang Actions
神州细胞关于召开2024年第一次临时股东大会的通知
AGM Information Classification · 95% confidence The document is a detailed notice about convening the 2024 first extraordinary general meeting (临时股东大会) of Beijing Sinocelltech Biotech Co., Ltd. It includes information about the meeting date, voting methods, agenda items, shareholder registration, and proxy voting instructions. The content focuses on the announcement and procedural details for the shareholders' meeting, including proposals to be voted on, but does not contain any financial statements, earnings data, or management discussion. It is not a report of voting results, nor a proxy solicitation document, but a formal meeting notice. Therefore, it fits the category of AGM Information (AGM-R), which covers presentations and materials shared during or for the Annual or Extraordinary General Meeting, including meeting notices and agendas.
2023-12-15 Chinese
神州细胞关于与特定对象签署附条件生效的股份认购协议暨关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding a conditional share subscription agreement with specific parties, including the company's actual controller and controlling shareholder. It discusses the issuance of shares to these specific parties, the pricing, subscription amounts, lock-up periods, and the necessary approvals from the board, shareholders, and regulatory bodies such as the Shanghai Stock Exchange and China Securities Regulatory Commission. The document also includes the independent directors' opinions and the sponsor's verification. This is a clear update on a capital raising activity involving share issuance to specific investors, which fits the category of Capital/Financing Update (CAP). The document is lengthy and detailed, not merely an announcement of a report or a brief notice, and it does not contain financial statements or earnings data, so it is not an Annual Report or Interim Report. It is not a regulatory filing or report publication announcement because it contains substantive transaction details. Therefore, the best classification is CAP with high confidence.
2023-12-15 Chinese
神州细胞关于修订《公司章程》及相关附件并办理工商备案登记的公告
Governance Information Classification · 95% confidence The document is a detailed announcement from Beijing Shenzhou Cell Biotechnology Group Co., Ltd. regarding revisions to the company's Articles of Association and related attachments, including governance rules such as shareholder meeting rules and board meeting rules. It includes specific amendments to corporate governance provisions, board and shareholder meeting procedures, director duties, and other internal governance matters. The document is not a financial report, earnings release, or audit report, nor is it a simple announcement of a report publication. It is a governance-related disclosure about changes to the company's internal rules and corporate governance structure. Therefore, the appropriate classification is Governance Information (CGR). The document length and detail support this classification with high confidence.
2023-12-15 Chinese
会计师事务所选聘制度
Governance Information Classification · 95% confidence The document is titled '北京神州细胞生物技术集团股份公司 会计师事务所选聘制度' which translates to 'Beijing Shenzhou Cell Biotechnology Group Co., Ltd. Auditor Selection System'. It details the procedures, requirements, and policies for selecting and appointing an accounting firm (auditor) for the company. The content includes legal references, internal governance rules, evaluation criteria, and procedural steps for auditor appointment and replacement. There is no financial data, audit report, or financial statements included. The document is a governance and procedural policy document related to auditor selection rather than an audit report or annual report. Therefore, it fits best under Governance Information (CGR), which covers internal rules and governance practices of the company.
2023-12-15 Chinese
神州细胞关于公司最近五年不存在被证券监管部门和交易所处罚或采取监管措施的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement from Beijing Shenzhou Cell Biotechnology Group Co., Ltd. stating that the company has not been subject to any penalties or regulatory measures by securities regulatory authorities or exchanges in the past five years. It is related to compliance and regulatory status, not a financial report or detailed management information. The document is brief (596 characters) and serves as a regulatory compliance announcement. It does not contain financial data, management changes, or voting results. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-12-15 Chinese
神州细胞第二届监事会第九次会议决议公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement of resolutions passed at the Supervisory Board meeting of Beijing Shenzhou Cell Biotechnology Group Co., Ltd. It includes approvals related to a specific capital raising activity: a private placement of A shares to specific investors, including the company's controlling shareholders. The document discusses the issuance terms, pricing, number of shares, use of proceeds, lock-up periods, and related party transactions. It also mentions that these resolutions require shareholder approval. The content is focused on the capital raising plan and related governance approvals rather than the actual issuance or financial results. This fits the definition of a Capital/Financing Update (CAP) as it provides updates on company fundraising and capital structure changes. The document is not a full financial report, audit, or regulatory filing, nor is it a voting result announcement or management change notice. Therefore, the most appropriate classification is CAP with high confidence.
2023-12-15 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.